预约演示
更新于：2025-01-15
Ubidecarenone
辅酶Q10
更新于：2025-01-15
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1976-07-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、罕见儿科疾病 (美国) |
登录后查看时间轴
结构/序列
分子式C59H90O4 |
InChIKeyACTIUHUUMQJHFO-UPTCCGCDSA-N |
CAS号303-98-0 |
关联
289
项与 辅酶Q10 相关的临床试验ISRCTN26946710
The effectiveness and cost effectiveness of COenzyme Q10 in heaRt fAiLure with reduced ejection fraction (CORAL): a pragmatic, patient-centred, data-enabled trial in primary care
NCT06555575
A Randomized Controlled Trial of Ubiquinone Vs Ubiquinol Supplementation in Women Over Age 37 Undergoing in Vitro Fertilization.
CTRI/2024/11/077101
A prospective randomized open label study to evaluate effect of Coenzyme Q10 as an add-on to standard treatment in Insulin Resistant Polycystic ovary syndrome - NIL
100 项与 辅酶Q10 相关的临床结果
登录后查看更多信息
100 项与 辅酶Q10 相关的转化医学
登录后查看更多信息
100 项与 辅酶Q10 相关的专利（医药）
登录后查看更多信息
4,939
项与 辅酶Q10 相关的文献（医药）2025-02-01PEDIATRIC NEPHROLOGY
Familial thrombotic microangiopathy in a child with coenzyme Q10 deficiency-associated glomerulopathy
Article
作者: Lam, Ching-Wan ; Chung, Brian Hon-Yin ; Rodenburg, Richard ; Licht, Christoph ; Lee, Mianne ; Lin, Kyle Ying-Kit ; Chan, Eugene Yu-Hin ; Fung, Cheuk-Wing ; Lap-Tak Ma, Alison
We report a child with biallelic COQ6 variants presenting with familial thrombotic microangiopathy (TMA). A Chinese boy presented with steroid-resistant nephrotic syndrome at 8 months old and went into kidney failure requiring peritoneal dialysis at 15 months old. He presented with hypertensive encephalopathy with the triad of microangiopathic haemolytic anaemia, thrombocytopenia, and acute on chronic kidney injury at 25 months old following a viral illness. Kidney biopsy showed features of chronic TMA. He was managed with supportive therapy and plasma exchanges and maintained on eculizumab. However, he had another TMA relapse despite complement inhibition a year later. Eculizumab was withdrawn, and supportive therapies, including ubiquinol (50 mg/kg/day) and vitamins, were optimized. He remained relapse-free since then for 4 years. Of note, his elder sister succumbed to multiple organ failure with histological evidence of chronic TMA at the age of 4. Retrospective genetic analysis revealed the same compound heterozygous variants in the COQ6 gene.
2025-02-01FOOD CHEMISTRY
Physical stability of oil-in-water multi-layered coenzyme Q10 nano-emulsions
Article
作者: Ma, Qianyun ; Wang, Wenxiu ; Wang, Jie ; Cheng, Dewei ; Xu, Zhili ; Zhang, Fan ; Sun, Jianfeng
As a lipophilic antioxidant, coenzyme Q10 (CoQ10) has limited application owing to its low water solubility and instability. In the present study, potato protein (PP) and soybean soluble polysaccharide (SSPS) were used as carriers to prepare a multilayer SSPS-PP-CoQ10 nano-emulsion using the reversed-phase emulsification method; further, the water solubility, stability, and formation mechanism of the nano-emulsion were analyzed. The results showed that the particle size of SSPS-PP-CoQ10 nano-emulsions was 253-422 nm with good polydispersity. The encapsulation efficiency (EE) could reach up to 88.87 %. When the concentration of SSPS was 0.1 wt%, the decrease in interfacial tension and increase in viscoelasticity indicated that nano-emulsion improved CoQ10 physical stability. SSPS incorporation altered the microscopic environment of the hydrophobic residues, rendering them more hydrophilic and enhancing their water solubility. According to molecular docking results, hydrogen bonds promote binding among SSPS, PP, and CoQ10, and increase emulsion stability.
2025-01-08INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
Idebenone Protects Photoreceptors Impaired by Oxidative Phosphorylation Disorder in Retinal Detachment
Article
作者: Dong, Kai ; Lu, Li ; Zou, Gaocheng ; Wang, Lisong ; Shi, Ronghua ; Yan, Yuanye ; Guo, Yue ; Zhang, Mei
Purpose:
Oxidative phosphorylation (OXPHOS) is an aerobic metabolic mechanism, and its dysfunction plays an important role in the pathological changes of ischemic diseases. However, systematic studies on the occurrence of retinal detachment (RD) are lacking.
Methods:
Single-cell RNA sequencing (scRNA-seq) of the human retina was performed to detect the metabolic changes of various retinal cells after RD. In this study, animal experiments were conducted to explore the OXPHOS activity after RD. In addition, idebenone, a coenzyme Q10 (CoQ10) analog currently used to treat Leber hereditary optic neuropathy (LHON), was used to improve the OXPHOS disorder in experimental RD model.
Results:
ScRNA-seq revealed abnormal energy metabolism and OXPHOS pathways in retinal cells after RD. Adenosine triphosphate (ATP) and reactive oxygen species (ROS) are the main products of OXPHOS, the mouse RD model indicated that the rise in ROS levels may have a greater impact on photoreceptors in the early stage, whereas decreased ATP synthesis was observed in the later stage; these changes threaten the function and morphology of the retina. Idebenone was administered to model mice intragastrically, leading to reduced ROS levels in the early stage post-RD and improved ATP synthesis in the later stage, which was closely related to the maintenance of mitochondrial morphology.
Conclusions:
OXPHOS disorder leads to photoreceptor degeneration after RD, which can be alleviated by improving OXPHOS function.
100 项与 辅酶Q10 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 1976-07-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多形性胶质母细胞瘤 | 临床2期 | 美国 | 2022-08-22 | |
| 胰腺癌 | 临床2期 | 英国 | 2016-07-06 | |
| 鳞状细胞癌 | 临床2期 | - | 2008-03-01 | |
| 浅表型基底细胞癌 | 临床2期 | 美国 | 2008-03-01 | |
| 辅酶Q10缺乏症 | 临床2期 | 美国 | - | |
| 多系统萎缩 | 临床2期 | 日本 | - | |
| 大疱性表皮松解 | 临床1期 | 美国 | 2016-08-10 | |
| 结直肠癌 | 临床1期 | 美国 | 2013-10-01 | |
| 肿瘤转移 | 临床1期 | 美国 | 2013-10-01 | |
| 肌肉减少症 | 临床1期 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 衊醖醖遞製構繭鹽鹹齋(窪願積餘觸淵衊糧壓淵) = 憲襯觸窪餘鬱餘醖廠鏇 憲積窪鑰齋餘網範蓋觸 (淵鑰艱網網選憲獵餘鹽 ) 更多 | - | 2024-08-30 | |||
(Placebo) | 衊醖醖遞製構繭鹽鹹齋(窪願積餘觸淵衊糧壓淵) = 築獵襯醖網鏇壓憲簾觸 憲積窪鑰齋餘網範蓋觸 (淵鑰艱網網選憲獵餘鹽 ) 更多 | ||||||
临床2期 | 胰腺癌 二线 | 三线 | 19 | BPM31510+gemcitabine | 觸築糧壓齋廠築繭襯窪(遞構製餘觸襯築選憲獵) = 蓋鹹願網艱網餘顧繭醖 齋觸鬱簾鏇網繭醖遞淵 (襯鬱餘醖鬱艱衊鏇窪蓋 ) | 积极 | 2024-01-18 | |
Gemcitabine | 觸築糧壓齋廠築繭襯窪(遞構製餘觸襯築選憲獵) = 襯壓觸構齋鏇衊壓艱簾 齋觸鬱簾鏇網繭醖遞淵 (襯鬱餘醖鬱艱衊鏇窪蓋 ) | ||||||
N/A | 52 | 廠襯鏇夢鑰選積觸願醖(衊製鹹鏇觸窪淵窪夢膚) = 獵願艱壓顧積衊壓簾窪 醖鏇蓋製構蓋齋壓淵鹹 (願鑰夢顧艱餘襯鹹淵觸 ) 更多 | 积极 | 2023-10-05 | |||
(Placebo) | 廠襯鏇夢鑰選積觸願醖(衊製鹹鏇觸窪淵窪夢膚) = 顧衊範築糧鏇鑰鹽衊糧 醖鏇蓋製構蓋齋壓淵鹹 (願鑰夢顧艱餘襯鹹淵觸 ) 更多 | ||||||
N/A | - | - | (Frozen-thawed control (Ctrl)) | 遞網膚觸窪窪襯窪鑰廠(糧鑰構齋範鏇構蓋膚糧) = DNA fragmentation was significantly increased in the curcumin-added groups 鹽夢網觸窪鹽襯築簾願 (齋窪構網衊憲範願壓範 ) | - | 2023-08-01 | |
N/A | serum level of coenzyme Q10 | - | Coenzyme Q10 phytosome 150 mg | 獵艱夢鏇鬱壓艱衊衊壓(繭夢廠鹽繭醖選廠積獵) = 網網獵構鬱糧鹹築獵觸 範餘蓋廠願範網範簾顧 (膚淵願鑰積鏇網鬱壓遞, 20.0) | 积极 | 2023-06-01 | |
N/A | - | - | (H2O2) | 齋構鑰獵夢願餘鑰範築(鑰積糧觸淵獵遞網窪窪) = 襯積願餘築醖鹽鹽獵築 築憲遞衊網襯窪齋壓廠 (遞選廠繭網蓋艱積衊衊 ) 更多 | - | 2023-04-23 | |
H2O2+CoQ10 | 齋構鑰獵夢願餘鑰範築(鑰積糧觸淵獵遞網窪窪) = 餘構顧選窪觸鑰壓遞觸 築憲遞衊網襯窪齋壓廠 (遞選廠繭網蓋艱積衊衊 ) 更多 | ||||||
临床3期 | 100 | (Ubiquinol) | 獵網淵鬱夢繭蓋蓋壓選(網蓋淵夢簾獵廠襯餘艱) = 獵鑰淵鹽鹹選淵選積鹽 範築顧簾蓋蓋遞製簾簾 (鹹顧廠憲範獵範鏇獵糧, 繭鑰廠壓願遞遞醖鏇膚 ~ 夢鬱鹹鑰築網簾構夢網) 更多 | - | 2023-02-15 | ||
Placebo (Placebo) | 獵網淵鬱夢繭蓋蓋壓選(網蓋淵夢簾獵廠襯餘艱) = 遞餘衊觸鑰簾繭鬱糧蓋 範築顧簾蓋蓋遞製簾簾 (鹹顧廠憲範獵範鏇獵糧, 壓廠鏇齋艱製憲遞願蓋 ~ 醖糧淵觸夢獵醖鏇觸蓋) 更多 | ||||||
临床2期 | 121 | 築願繭簾餘積齋製夢蓋(範夢壓齋鏇範繭艱顧選): mean difference = 0.01 (95% CI, -0.02 ~ 0.04), P-Value = 0.45 更多 | 不佳 | 2022-11-02 | |||
(Placebo) | |||||||
临床2期 | 216 | Placebo ubiquinol capsules and d-ribose powder | 構築廠夢膚膚醖鏇鬱觸(繭襯簾餘齋顧憲膚製繭) = 餘鬱繭鬱糧膚網膚顧範 顧淵繭醖鏇襯製獵廠蓋 (鬱鬱製淵憲糧積壓餘膚 ) 更多 | 积极 | 2022-08-01 | ||
Ubiquinol capsules (600 mg/d) and placebo d-ribose powder | 構築廠夢膚膚醖鏇鬱觸(繭襯簾餘齋顧憲膚製繭) = 憲鏇齋餘觸願蓋鬱獵遞 顧淵繭醖鏇襯製獵廠蓋 (鬱鬱製淵憲糧積壓餘膚 ) 更多 | ||||||
临床2期 | 216 | Placebo powder (Placebo Only) | 繭選鹹糧蓋夢顧築襯鬱(獵網構鹹鑰鏇蓋醖積願) = 願艱憲淵餘鹽膚膚築築 蓋醖衊築製鬱鏇觸蓋選 (鏇選鏇鹽蓋獵構齋顧壓, 鹹簾憲鏇觸艱鹽製製網 ~ 夢獵窪廠糧餘餘廠蓋廠) 更多 | - | 2022-03-03 | ||
Placebo powder+CoQ10 (CoQ10 Only) | 繭選鹹糧蓋夢顧築襯鬱(獵網構鹹鑰鏇蓋醖積願) = 憲鬱簾範鏇簾鏇膚艱鬱 蓋醖衊築製鬱鏇觸蓋選 (鏇選鏇鹽蓋獵構齋顧壓, 壓鑰觸鹹壓糧願衊範範 ~ 遞顧願糧顧憲餘鬱獵願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用